Open Access Articles

HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles

, 2017; 17(7): 637 - 649

Sarah L. Sammons, Donna L. Topping and Kimberly L. Blackwell*

Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer

, 2016; 16(4): 346 - 356

Xue-Qing Hu, Yang Sun, Eric Lau, Ming Zhao and Shi-Bing Su

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

, 2015; 15(8): 665 - 683

Otília Menyhart, Libero Santarpia and Balazs Gyorffy

Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives

, 2015; 15(3): 256 - 269

Rena Chiotaki, Hara Polioudaki and Panayiotis A. Theodoropoulos

Platycodin D Induces Tumor Growth Arrest by Activating FOXO3a Expression in Prostate Cancer in vitro and in vivo

, 2014; 14(9): 860 - 871

Rui Zhou, Zongliang Lu, Kai Liu, Jing Guo, Jie Liu, Yong Zhou, Jian Yang, Mantian Mi and Hongxia Xu

Pleiotropic Role of HSF1 in Neoplastic Transformation

, 2014; 14(2): 144 - 155

Natalia Vydra, Agnieszka Toma and Wieslawa Widlak

MicroRNAs as Critical Regulators Involved in Regulating Epithelial- Mesenchymal Transition

, 2013; 13(9): 935 - 944

Xiaodi Zhao, Yuanyuan Lu, Yongzhan Nie and Daiming Fan

Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition

, 2013; 13(9): 906 - 914

Asfar S. Azmi

β-Catenin Knockdown in Liver Tumor Cells by a Cell Permeable Gamma Guanidine-based Peptide Nucleic Acid

, 2013; 13(8): 867 - 878

Evan Delgado, Raman Bahal, Jing Yang, Jung M. Lee, Danith H Ly and Satdarshan P. S. Monga

Signal Transduction in Human Cutaneous Melanoma and Target Drugs

, 2013; 13(8): 843 - 866

Anatoly B. Uzdensky, Svetlana V. Demyanenko and Mikhail Y. Bibov

Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia

, 2013; 13(7): 791 - 810

Ilaria Iacobucci, Annalisa Lonetti, Cristina Papayannidis and Giovanni Martinelli

Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy

, 2013; 13(7): 724 - 734

Gudmundur V. Helgason, Arunima Mukhopadhyay, Maria Karvela, Paolo Salomoni, Bruno Calabretta and Tessa L. Holyoake

New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy

, 2013; 13(7): 711 - 723

Michele Cea, Antonia Cagnetta, Alessio Nencioni, Marco Gobbi and Franco Patrone

Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways

, 2013; 13(6): 698 - 707

Vijaya Galic, Robert L. Coleman and Thomas J. Herzog

Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy

, 2013; 13(6): 670 - 685

Khaled Ghattass, Rana Assah, Marwan El-Sabban and Hala Gali-Muhtasib

Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer

, 2013; 13(5): 542 - 557

Venkateshwar Madka and Chinthalapally V. Rao

miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents

, 2013; 13(5): 519 - 541

Biyun Qian, Subhasree A. Nag, Yuliang Su, Sukesh Voruganti, Jiang-Jiang Qin, Ruiwen Zhang and William C. S. Cho

VEGF in Tumor Progression and Targeted Therapy

, 2013; 13(4): 423 - 443

Vladimir P. Chekhonin, Sergey A. Shein, Anna A. Korchagina and Olga I. Gurina

Nanomedicines as Cancer Therapeutics: Current Status

, 2013; 13(4): 362 - 378

Sohail Akhter, Iqbal Ahmad, Mohammad Zaki Ahmad, Farshad Ramazani, Anjali Singh, Ziyaur Rahman, Farhan Jalees Ahmad, Gert Storm and Robbert J. Kok

P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives

, 2013; 13(3): 326 - 346

Ziyad Binkhathlan and Afsaneh Lavasanifar

Targeting Tyrosine Kinase Receptors in Hepatocellular Carcinoma

, 2013; 13(3): 300 - 312

Jordi Muntane, Angel J. De la Rosa, Fernando Docobo, Rocio Garcia-Carbonero and Francisco J. Padillo

Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling

, 2013; 13(2): 188 - 204

Thomas W. Grunt and Gabriella L. Mariani

Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer

, 2013; 13(2): 175 - 187

Xiaobei Zhang, Xi-ru Li and Jin Zhang

Cancer Stem Cell as a Potential Therapeutic Target in Hepatocellular Carcinoma

, 2012; 12(9): 1081 - 1094

Roberta W.C. Pang and Ronnie T.P. Poon

Targeted Therapy for Liver Cancer: Updated Review in 2012

, 2012; 12(9): 1062 - 1072

Masatoshi Kudo

Scope of Nanotechnology-based Radiation Therapy and Thermotherapy Methods in Cancer Treatment

, 2012; 12(8): 998 - 1015

Mohamadreza K. Bakht, Mahdi Sadeghi, Milad Pourbaghi-Masouleh and Claudio Tenreiro

Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs

, 2012; 12(8): 962 - 986

Johnson J. Liu, Jun Lu and Mark J. McKeage

A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma

, 2012; 12(7): 857 - 872

Z. Mihaly, Z. Sztupinszki, P. Surowiak and B. Gyorffy

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma

, 2012; 12(7): 838 - 846

P. Tagliaferri, M. Rossi, M. T. Di Martino, N. Amodio, E. Leone, A. Gulla, A. Neri and P. Tassone

MicroRNAs in the Pathobiology of Multiple Myeloma

, 2012; 12(7): 823 - 837

Marta Lionetti, Luca Agnelli, Luigia Lombardi, Pierfrancesco Tassone and Antonino Neri

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma

, 2012; 12(7): 814 - 822

P. Tassone, P. Neri, R. Burger, M. T. Di Martino, E. Leone, N. Amodio, M. Caraglia and P. Tagliaferri

Molecular Targets for the Treatment of Multiple Myeloma

, 2012; 12(7): 757 - 767

Marco Rossi, Maria Teresa Di Martino, Eugenio Morelli, Marzia Leotta, Antonietta Rizzo, Anna Grimaldi, Gabriella Misso, Pierfrancesco Tassone and Michele Caraglia

Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention

, 2012; 12(6): 716 - 740

K. Neelakandan, P. Babu and S. Nair

High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer

, 2012; 12(6): 693 - 702

C. D'Alterio, L. Portella, A. Ottaiano, M. Rizzo, G. Carteni, S. Pignata, G. Facchini, S. Perdona, G. Di Lorenzo, R. Autorino, R. Franco, A. La Mura, O. Nappi, G. Castello and S. Scala

Two Novel GPER Agonists Induce Gene Expression Changes and Growth Effects in Cancer Cells

, 2012; 12(5): 531 - 542

R. Lappano, C. Rosano, M. F. Santolla, M. Pupo, E. M. De Francesco, P. De Marco, M. Ponassi, A. Spallarossa, A. Ranise and M. Maggiolini

Emerging Therapies in Chronic Myeloid Leukemia

, 2012; 12(5): 458 - 470

J. Gora-Tybor

An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors

, 2012; 12(4): 439 - 452

Nicola Tinari, Michele De Tursi, Antonino Grassadonia, Marinella Zilli, Liborio Stuppia, Stefano Iacobelli and Clara Natoli

Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs

, 2012; 12(4): 402 - 438

J. J.G. Marin, O. Briz, M. J. Monte, A. G. Blazquez and R. I.R. Macias

Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance

, 2012; 12(3): 197 - 209

T. E. Taylor, F. B. Furnari and W. K. Cavenee

Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood- Brain-Barrier

, 2012; 12(3): 186 - 196

M. Caraglia, G. De Rosa, G. Salzano, D. Santini, M. Lamberti, P. Sperlongano, A. Lombardi, A. Abbruzzese and R. Addeo

Anticancer Drugs Aimed at E6 and E7 Activity in HPV-Positive Cervical Cancer

, 2012; 12(2): 170 - 184

S. Tan, E. G.E. de Vries, A. G.J. van der Zee and S. de Jong

Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer

, 2012; 12(2): 107 - 123

S. A. Kono, L. E. Heasley, R. C. Doebele and D. R. Camidge

Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy

, 2011; 11(7): 826 - 836

B. B. Cheung and G. M. Marshall

Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway

, 2010; 10(8): 824 - 833

A. J. Weickhardt, N. C. Tebbutt and J. M. Mariadason

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

, 2010; 10(2): 155 - 167

A. K. Gandhi, J. Kang, L. Capone, A. Parton, L. Wu, L. H. Zhang, D. Mendy, A. Lopez-Girona, T. Tran, L. Sapinoso, W. Fang, S. Xu, G. Hampton, J. B. Bartlett and P. Schafer

Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy

, 2009; 9(4): 572 - 594

Qi Zhao Wang, William Xu, Nagy Habib and Ruian Xu

S100A8 and S100A9 Overexpression Is Associated with Poor Pathological Parameters in Invasive Ductal Carcinoma of the Breast

, 2008; 8(4): 243 - 252

Kazumori Arai, Sachiko Takano, Takumi Teratani, Yasuhiro Ito, Toshihiro Yamada and Ryushi Nozawa

Nutritional Modulation of Terminal End Buds: Its Relevance to Breast Cancer Prevention

, 2007; 7(5): 465 - 474

Leena Hilakivi-Clarke

Ribonucleotide Reductase Inhibitors and Future Drug Design

, 2006; 6(5): 409 - 431

J. Shao, B. Zhou, Bernard Chu and Y. Yen

Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of Osteosarcoma

, 2006; 6(2): 123 - 133

A. Nardin, M. L. Lefebvre, K. Labroquere, O. Faure and J. P. Abastado

Webmaster Contact:
Copyright © 2018 Bentham Science